超6成私募产品业绩创新高！15只“双十基金”产品在列！

Core Insights - The performance of private equity products reached a historical high in July 2025, with A-share indices showing significant upward trends, with the Shanghai Composite Index rising by 3.74%, the Shenzhen Component Index by 5.20%, and the ChiNext Index by 8.14% [1] - A total of 2,761 private equity products achieved historical net value highs in July 2025, representing approximately 60.43% of the products with performance data available for nearly one year [1] - Among these products, 1,214 were quantitative, while 1,547 were non-quantitative, with stock strategy products being the most prevalent, accounting for about 60% [1][2] Group 1: Product Performance - The majority of high-performing products came from private equity firms with assets under management below 500 million, totaling 1,122 products, while 379 products were from firms managing over 10 billion [2] - There were 21 products that had been established for over 10 years, with 15 of them classified as "Double Ten Funds," indicating annualized returns exceeding 10% [2] Group 2: Strategy Breakdown - The top-performing private equity products by strategy included 1,654 stock strategy products, 393 multi-asset strategy products, 327 futures and derivatives strategy products, 290 bond strategy products, and 97 combination fund products [1][2] - In the quantitative stock strategy category, there were 478 products, with the top 20 yielding over a specified threshold [6][10] Group 3: Notable Firms and Managers - Notable firms included Hainan Shengfeng Private Equity, which had a product ranked 9th among the top 20, with a recent scale of approximately *** billion and a near one-year return close to ***% [10] - The top-performing product in the subjective long strategy category was managed by Nengjing Investment Holdings, which had two products in the top rankings [11][13] Group 4: Sector Insights - The private equity market is currently characterized by a bullish sentiment, with high expectations for quality growth stocks, particularly in sectors like innovative pharmaceuticals, AI, and stablecoin financial innovations [5] - The bond strategy products also showed strong performance, with 203 products achieving historical highs, and the top five returns coming from firms like Yuankang Private Equity and Jiaze Fund [24][25]